메뉴 건너뛰기




Volumn 62, Issue 1, 2013, Pages 13-21

Heart failure with preserved ejection fraction: Emerging drug strategies

Author keywords

cardiac remodeling; cardiomyocyte stiffness; diastolic dysfunction; extracellular matrix; heart failure; hypertension; preserved ejection fraction

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALAGEBRIUM; ALGEBRIUM; CARDIOVASCULAR AGENT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; HISDN; INTERLEUKIN 6; INTERLEUKIN 8; IVABRADINE; NITRIC OXIDE; PERINDOPRIL; RANOLAZINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; S 31 201; SILDENAFIL; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UDENAFIL; UNCLASSIFIED DRUG; VALSARTAN;

EID: 84880571722     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31829a4e61     Document Type: Article
Times cited : (51)

References (87)
  • 1
    • 79952829685 scopus 로고    scopus 로고
    • Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment
    • Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
    • (2011) Eur Heart J. , vol.32 , pp. 670-679
    • Borlaug, B.A.1    Paulus, W.J.2
  • 2
    • 84863633337 scopus 로고    scopus 로고
    • The pathophysiology of heart failure with preserved ejection fraction: From molecular mechanisms to exercise haemodynamics
    • Phan TT, Shivu GN, Abozguia K, et al. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. Int J Cardiol. 2012;158:337-343.
    • (2012) Int J Cardiol. , vol.158 , pp. 337-343
    • Phan, T.T.1    Shivu, G.N.2    Abozguia, K.3
  • 3
    • 84873432602 scopus 로고    scopus 로고
    • Heart failure with preserved ejection fraction: Current understanding and emerging concepts
    • Liu Y, Haddad T, Dwivedi G. Heart failure with preserved ejection fraction: current understanding and emerging concepts. Curr Opin Cardiol. 2013;28:187-196.
    • (2013) Curr Opin Cardiol. , vol.28 , pp. 187-196
    • Liu, Y.1    Haddad, T.2    Dwivedi, G.3
  • 4
    • 77952537910 scopus 로고    scopus 로고
    • Hypertension as an underlying factor in heart failure with preserved ejection fraction
    • Volpe M, McKelvie R, Drexler H. Hypertension as an underlying factor in heart failure with preserved ejection fraction. J Clin Hypertens (Greenwich). 2010;12:277-283.
    • (2010) J Clin Hypertens (Greenwich). , vol.12 , pp. 277-283
    • Volpe, M.1    McKelvie, R.2    Drexler, H.3
  • 5
    • 79957505248 scopus 로고    scopus 로고
    • Heart failure with preserved left ventricular ejection fraction: Concepts, misconceptions and future directions
    • Soma J. Heart failure with preserved left ventricular ejection fraction: concepts, misconceptions and future directions. Blood Press. 2011;20:129-133.
    • (2011) Blood Press. , vol.20 , pp. 129-133
    • Soma, J.1
  • 6
    • 79952474816 scopus 로고    scopus 로고
    • Treatment of heart failure with preserved ejection fraction
    • Barnes MM, Dorsch MP, Hummel SL, et al. Treatment of heart failure with preserved ejection fraction. Pharmacotherapy. 2011;31:312-331.
    • (2011) Pharmacotherapy. , vol.31 , pp. 312-331
    • Barnes, M.M.1    Dorsch, M.P.2    Hummel, S.L.3
  • 7
    • 84870556584 scopus 로고    scopus 로고
    • What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE
    • Campbell RT, Jhund PS, Castagno D, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012;60: 2349-2356.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 2349-2356
    • Campbell, R.T.1    Jhund, P.S.2    Castagno, D.3
  • 8
    • 33750995868 scopus 로고    scopus 로고
    • Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction
    • Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138-2147.
    • (2006) Circulation. , vol.114 , pp. 2138-2147
    • Borlaug, B.A.1    Melenovsky, V.2    Russell, S.D.3
  • 9
    • 84875766051 scopus 로고    scopus 로고
    • B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
    • van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-1506.
    • (2013) J Am Coll Cardiol. , vol.61 , pp. 1498-1506
    • Van Veldhuisen, D.J.1    Linssen, G.C.2    Jaarsma, T.3
  • 10
    • 75249087216 scopus 로고    scopus 로고
    • Treatment of heart failure with normal ejection fraction: An inconvenient truth
    • Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55:526-537.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 526-537
    • Paulus, W.J.1    Van Ballegoij, J.J.2
  • 11
    • 34548414571 scopus 로고    scopus 로고
    • Myocardial fibrosis and diastolic dysfunction in patients with hypertension: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
    • Müller-Brunotte R, Kahan T, López B, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007;25:1958-1966.
    • (2007) J Hypertens. , vol.25 , pp. 1958-1966
    • Müller-Brunotte, R.1    Kahan, T.2    López, B.3
  • 12
    • 21244477144 scopus 로고    scopus 로고
    • Early recognition and treatment of hypertensive heart disease
    • Mitchell JA, Ventura HO, Mehra MR. Early recognition and treatment of hypertensive heart disease. Curr Opin Cardiol. 2005;20:282-289.
    • (2005) Curr Opin Cardiol. , vol.20 , pp. 282-289
    • Mitchell, J.A.1    Ventura, H.O.2    Mehra, M.R.3
  • 13
    • 80053246717 scopus 로고    scopus 로고
    • Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure
    • Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13:1087-1095.
    • (2011) Eur J Heart Fail , vol.13 , pp. 1087-1095
    • Collier, P.1    Watson, C.J.2    Voon, V.3
  • 14
    • 81755174888 scopus 로고    scopus 로고
    • Matrix metalloproteinase-9 induces cardiac fibroblast migration, collagen and cytokine secretion: Inhibition by salvianolic acid B from Salvia miltiorrhiza
    • Wang Y, Xu F, Chen J, et al. Matrix metalloproteinase-9 induces cardiac fibroblast migration, collagen and cytokine secretion: inhibition by salvianolic acid B from Salvia miltiorrhiza. Phytomedicine. 2011;19:13-19.
    • (2011) Phytomedicine. , vol.19 , pp. 13-19
    • Wang, Y.1    Xu, F.2    Chen, J.3
  • 15
    • 0034650486 scopus 로고    scopus 로고
    • Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis
    • Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163-176.
    • (2000) Genes Dev. , vol.14 , pp. 163-176
    • Yu, Q.1    Stamenkovic, I.2
  • 16
    • 84881479585 scopus 로고    scopus 로고
    • Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function
    • Epub ahead of print
    • Chu JW, Jones GT, Tarr GP, et al. Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. Int J Cardiol. 2012. Epub ahead of print.
    • (2012) Int J Cardiol.
    • Chu, J.W.1    Jones, G.T.2    Tarr, G.P.3
  • 17
    • 64549091944 scopus 로고    scopus 로고
    • Diagnosis of heart failure with preserved ejection fraction: Improved accuracy with the use of markers of collagen turnover
    • Martos R, Baugh J, Ledwidge M, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197.
    • (2009) Eur J Heart Fail. , vol.11 , pp. 191-197
    • Martos, R.1    Baugh, J.2    Ledwidge, M.3
  • 18
    • 84856028941 scopus 로고    scopus 로고
    • Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction
    • de Denus S, Lavoie J, Ducharme A, et al. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol. 2012;28:62-68.
    • (2012) Can J Cardiol. , vol.28 , pp. 62-68
    • De Denus, S.1    Lavoie, J.2    Ducharme, A.3
  • 19
    • 84870425373 scopus 로고    scopus 로고
    • Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction
    • Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2012;14:1338-1347.
    • (2012) Eur J Heart Fail. , vol.14 , pp. 1338-1347
    • Santhanakrishnan, R.1    Chong, J.P.2    Ng, T.P.3
  • 20
    • 79957777288 scopus 로고    scopus 로고
    • Treatment of heart failure with preserved ejection fraction: Have we been pursuing the wrong paradigm
    • Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc. 2011;86:531-539.
    • (2011) Mayo Clin Proc , vol.86 , pp. 531-539
    • Oghlakian, G.O.1    Sipahi, I.2    Fang, J.C.3
  • 21
    • 84867883843 scopus 로고    scopus 로고
    • Endothelial dysfunction: A pathophysiologic factor in heart failure with preserved ejection fraction
    • Lam CS, Brutsaert DL. Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2012;60:1787-1789.
    • (2012) J Am Coll Cardiol. , vol.60 , pp. 1787-1789
    • Lam, C.S.1    Brutsaert, D.L.2
  • 22
    • 67650547206 scopus 로고    scopus 로고
    • Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency
    • Phan TT, Abozguia K, Nallur Shivu G, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54:402-409.
    • (2009) J Am Coll Cardiol. , vol.54 , pp. 402-409
    • Phan, T.T.1    Abozguia, K.2    Nallur Shivu, G.3
  • 23
    • 33748668461 scopus 로고    scopus 로고
    • Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium
    • Smith CS, Bottomley PA, Schulman SP, et al. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151-1158.
    • (2006) Circulation. , vol.114 , pp. 1151-1158
    • Smith, C.S.1    Bottomley, P.A.2    Schulman, S.P.3
  • 24
    • 0036272927 scopus 로고    scopus 로고
    • Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart
    • Yamamoto K, Masuyama T, Sakata Y, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002;55:76-82.
    • (2002) Cardiovasc Res. , vol.55 , pp. 76-82
    • Yamamoto, K.1    Masuyama, T.2    Sakata, Y.3
  • 25
    • 0030848551 scopus 로고    scopus 로고
    • Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats
    • Norton GR, Tsotetsi J, Trifunovic B, et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation. 1997;96: 1991-1998.
    • (1997) Circulation. , vol.96 , pp. 1991-1998
    • Norton, G.R.1    Tsotetsi, J.2    Trifunovic, B.3
  • 26
    • 79952260400 scopus 로고    scopus 로고
    • Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction
    • Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44-52.
    • (2011) Circ Heart Fail. , vol.4 , pp. 44-52
    • Westermann, D.1    Lindner, D.2    Kasner, M.3
  • 27
    • 77952958509 scopus 로고    scopus 로고
    • Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction
    • González A, López B, Querejeta R, et al. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010;55:1418-1424.
    • (2010) Hypertension. , vol.55 , pp. 1418-1424
    • González, A.1    López, B.2    Querejeta, R.3
  • 28
    • 81855171057 scopus 로고    scopus 로고
    • Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen substudy
    • Krum H, Elsik M, Schneider HG, et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011;4:561-568.
    • (2011) Circ Heart Fail. , vol.4 , pp. 561-568
    • Krum, H.1    Elsik, M.2    Schneider, H.G.3
  • 29
    • 13844255076 scopus 로고    scopus 로고
    • Cardiomyocyte stiffness in diastolic heart failure
    • Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781.
    • (2005) Circulation. , vol.111 , pp. 774-781
    • Borbély, A.1    Van Der Velden, J.2    Papp, Z.3
  • 30
    • 33646171304 scopus 로고    scopus 로고
    • Myocardial structure and function differ in systolic and diastolic heart failure
    • van Heerebeek L, Borbély A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973.
    • (2006) Circulation. , vol.113 , pp. 1966-1973
    • Van Heerebeek, L.1    Borbély, A.2    Niessen, H.W.3
  • 32
    • 84878871182 scopus 로고    scopus 로고
    • Tuning the molecular giant titin through phosphorylation: Role in health and disease
    • Hidalgo C, Granzier H. Tuning the molecular giant titin through phosphorylation: Role in health and disease. Trends Cardiovasc Med. 2013; 23:165-171.
    • (2013) Trends Cardiovasc Med. , vol.23 , pp. 165-171
    • Hidalgo, C.1    Granzier, H.2
  • 33
    • 59649084739 scopus 로고    scopus 로고
    • Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs
    • Krüger M, Kötter S, Grützner A, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87-94.
    • (2009) Circ Res. , vol.104 , pp. 87-94
    • Krüger, M.1    Kötter, S.2    Grützner, A.3
  • 34
    • 84856008116 scopus 로고    scopus 로고
    • Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: From contractility to remodeling
    • Hammond J, Balligand JL. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol. 2012;52:330-340.
    • (2012) J Mol Cell Cardiol. , vol.52 , pp. 330-340
    • Hammond, J.1    Balligand, J.L.2
  • 35
    • 77957331055 scopus 로고    scopus 로고
    • Modulation of vascular sarco/endoplasmic reticulum calcium ATPase in cardiovascular pathophysiology
    • Adachi T. Modulation of vascular sarco/endoplasmic reticulum calcium ATPase in cardiovascular pathophysiology. Adv Pharmacol. 2010;59: 165-195.
    • (2010) Adv Pharmacol. , vol.59 , pp. 165-195
    • Adachi, T.1
  • 36
    • 3042616583 scopus 로고    scopus 로고
    • Nitric oxide's role in the heart: Control of beating or breathing
    • Paulus WJ, Bronzwaer JG. Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol. 2004;287:H8-H13.
    • (2004) Am J Physiol Heart Circ Physiol , vol.287
    • Paulus, W.J.1    Bronzwaer, J.G.2
  • 37
    • 77952749684 scopus 로고    scopus 로고
    • PDE5A suppression of acute badrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin i phosphorylation
    • Lee DI, Vahebi S, Tocchetti CG, et al. PDE5A suppression of acute badrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol. 2010;105:337-347.
    • (2010) Basic Res Cardiol. , vol.105 , pp. 337-347
    • Lee, D.I.1    Vahebi, S.2    Tocchetti, C.G.3
  • 38
    • 14644417845 scopus 로고    scopus 로고
    • Putting the brakes on cardiac hypertrophy: Exploiting the NOcGMP counter-regulatory system
    • Booz GW. Putting the brakes on cardiac hypertrophy: exploiting the NOcGMP counter-regulatory system. Hypertension. 2005;45:341-346.
    • (2005) Hypertension. , vol.45 , pp. 341-346
    • Booz, G.W.1
  • 39
    • 84865209443 scopus 로고    scopus 로고
    • Low myocardial protein kinase G activity in heart failure with preserved ejection fraction
    • van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839.
    • (2012) Circulation. , vol.126 , pp. 830-839
    • Van Heerebeek, L.1    Hamdani, N.2    Falcão-Pires, I.3
  • 40
    • 84876699100 scopus 로고    scopus 로고
    • Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN])
    • CVRN PRESERVE HF Investigators.
    • Goldberg RJ, Gurwitz JH, Saczynski JS, et al; CVRN PRESERVE HF Investigators. Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]). Am J Cardiol. 2013; 111:1324-1329.
    • (2013) Am J Cardiol. , vol.111 , pp. 1324-1329
    • Goldberg, R.J.1    Gurwitz, J.H.2    Saczynski, J.S.3
  • 41
    • 84869825707 scopus 로고    scopus 로고
    • Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction
    • Lund LH, Benson L, Dahlström U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108-2117.
    • (2012) JAMA. , vol.308 , pp. 2108-2117
    • Lund, L.H.1    Benson, L.2    Dahlström, U.3
  • 42
    • 79960984168 scopus 로고    scopus 로고
    • Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)
    • Deswal A, Richardson P, Bozkurt B, et al. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17:634-642.
    • (2011) J Card Fail. , vol.17 , pp. 634-642
    • Deswal, A.1    Richardson, P.2    Bozkurt, B.3
  • 43
    • 33748988737 scopus 로고    scopus 로고
    • The perindopril in elderly people with chronic heart failure (PEP-CHF) study
    • Cleland JG, Tendera M, Adamus J, et al; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
    • (2006) Eur Heart J. , vol.27 , pp. 2338-2345
    • Cleland, J.G.1    Tendera, M.2    Adamus, J.3
  • 44
    • 84856203229 scopus 로고    scopus 로고
    • Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: Results of the ELANDD study
    • Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219-225.
    • (2012) Eur J Heart Fail. , vol.14 , pp. 219-225
    • Conraads, V.M.1    Metra, M.2    Kamp, O.3
  • 45
    • 84871210322 scopus 로고    scopus 로고
    • Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF)
    • Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110-118.
    • (2013) Eur J Heart Fail. , vol.15 , pp. 110-118
    • Yamamoto, K.1    Origasa, H.2    Hori, M.3
  • 46
    • 0041408234 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial
    • CHARM Investigators and Committees.
    • Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
    • (2003) Lancet. , vol.362 , pp. 777-781
    • Yusuf, S.1    Pfeffer, M.A.2    Swedberg, K.3
  • 47
    • 84860802725 scopus 로고    scopus 로고
    • Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial
    • I-PRESERVE Trial Investigators.
    • Rector TS, Carson PE, Anand IS, et al; I-PRESERVE Trial Investigators. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012;5:217-225.
    • (2012) Circ Heart Fail. , vol.5 , pp. 217-225
    • Rector, T.S.1    Carson, P.E.2    Anand, I.S.3
  • 48
    • 62949201759 scopus 로고    scopus 로고
    • Statin therapy and clinical outcomes in heart failure: A propensity-matched analysis
    • Ouzounian M, Tu JV, Austin PC, et al. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail. 2009; 15:241-248.
    • (2009) J Card Fail. , vol.15 , pp. 241-248
    • Ouzounian, M.1    Tu, J.V.2    Austin, P.C.3
  • 49
    • 84877259591 scopus 로고    scopus 로고
    • Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
    • Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184-192.
    • (2013) Circ Heart Fail. , vol.6 , pp. 184-192
    • Shah, S.J.1    Heitner, J.F.2    Sweitzer, N.K.3
  • 50
    • 84860218769 scopus 로고    scopus 로고
    • Role of heart rate reduction in the prevention of experimental heart failure: Comparison between If-channel blockade and b-receptor blockade
    • Becher PM, Lindner D, Miteva K, et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and b-receptor blockade. Hypertension. 2012;59:949-957.
    • (2012) Hypertension. , vol.59 , pp. 949-957
    • Becher, P.M.1    Lindner, D.2    Miteva, K.3
  • 51
    • 84873424901 scopus 로고    scopus 로고
    • Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction
    • Epub ahead of print
    • Reil JC, Hohl M, Reil GH, et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2012. Epub ahead of print.
    • (2012) Eur Heart J.
    • Reil, J.C.1    Hohl, M.2    Reil, G.H.3
  • 52
    • 84862776882 scopus 로고    scopus 로고
    • Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity
    • Lovelock JD, Monasky MM, Jeong EM, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110:841-850.
    • (2012) Circ Res. , vol.110 , pp. 841-850
    • Lovelock, J.D.1    Monasky, M.M.2    Jeong, E.M.3
  • 53
    • 84873140248 scopus 로고    scopus 로고
    • Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties
    • Jeong EM, Monasky MM, Gu L, et al. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol. 2013;56:44-54.
    • (2013) J Mol Cell Cardiol. , vol.56 , pp. 44-54
    • Jeong, E.M.1    Monasky, M.M.2    Gu, L.3
  • 54
    • 80052807512 scopus 로고    scopus 로고
    • Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure
    • Moens AL, Ketner EA, Takimoto E, et al. Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:564-569.
    • (2011) J Mol Cell Cardiol. , vol.51 , pp. 564-569
    • Moens, A.L.1    Ketner, E.A.2    Takimoto, E.3
  • 55
    • 80051978810 scopus 로고    scopus 로고
    • Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling
    • Förstermann U, Li H. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol. 2011;164:213-223.
    • (2011) Br J Pharmacol. , vol.164 , pp. 213-223
    • Förstermann, U.1    Li, H.2
  • 56
    • 42449083767 scopus 로고    scopus 로고
    • Antiatherosclerotic effects of smallmolecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling
    • Wohlfart P, Xu H, Endlich A, et al. Antiatherosclerotic effects of smallmolecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008;325:370-379.
    • (2008) J Pharmacol Exp Ther. , vol.325 , pp. 370-379
    • Wohlfart, P.1    Xu, H.2    Endlich, A.3
  • 57
    • 70349659801 scopus 로고    scopus 로고
    • Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure
    • Westermann D, Riad A, Richter U, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. 2009;104:499-509.
    • (2009) Basic Res Cardiol. , vol.104 , pp. 499-509
    • Westermann, D.1    Riad, A.2    Richter, U.3
  • 58
    • 79953775326 scopus 로고    scopus 로고
    • Playing with cardiac "redox switches": The "hNO way" to modulate cardiac function
    • Tocchetti CG, Stanley BA, Murray CI, et al. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011;14:1687-1698.
    • (2011) Antioxid Redox Signal. , vol.14 , pp. 1687-1698
    • Tocchetti, C.G.1    Stanley, B.A.2    Murray, C.I.3
  • 59
    • 84866990581 scopus 로고    scopus 로고
    • Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function
    • Gao WD, Murray CI, Tian Y, et al. Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res. 2012;111:1002-1011.
    • (2012) Circ Res. , vol.111 , pp. 1002-1011
    • Gao, W.D.1    Murray, C.I.2    Tian, Y.3
  • 60
    • 57649128299 scopus 로고    scopus 로고
    • Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl
    • Froehlich JP, Mahaney JE, Keceli G, et al. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry. 2008;47:13150-13152.
    • (2008) Biochemistry. , vol.47 , pp. 13150-13152
    • Froehlich, J.P.1    Mahaney, J.E.2    Keceli, G.3
  • 61
    • 8644291670 scopus 로고    scopus 로고
    • Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors
    • Cheong E, Tumbev V, Abramson J, et al. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium. 2005;37:87-96.
    • (2005) Cell Calcium. , vol.37 , pp. 87-96
    • Cheong, E.1    Tumbev, V.2    Abramson, J.3
  • 62
    • 0037884933 scopus 로고    scopus 로고
    • Positive inotropic and lusitropic effects of HNO/NO-in failing hearts: Independence from b-adrenergic signaling
    • Paolocci N, Katori T, Champion HC, et al. Positive inotropic and lusitropic effects of HNO/NO-in failing hearts: independence from b-adrenergic signaling. Proc Natl Acad Sci U S A. 2003;100:5537-5542.
    • (2003) Proc Natl Acad Sci U S A. , vol.100 , pp. 5537-5542
    • Paolocci, N.1    Katori, T.2    Champion, H.C.3
  • 63
    • 84869389745 scopus 로고    scopus 로고
    • Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice
    • Chiao YA, Ramirez TA, Zamilpa R, et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res. 2012;96:444-455.
    • (2012) Cardiovasc Res. , vol.96 , pp. 444-455
    • Chiao, Y.A.1    Ramirez, T.A.2    Zamilpa, R.3
  • 64
    • 50649119519 scopus 로고    scopus 로고
    • Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition
    • Lauer-Fields JL, Whitehead JK, Li S, et al. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem. 2008;283:20087-20095.
    • (2008) J Biol Chem. , vol.283 , pp. 20087-20095
    • Lauer-Fields, J.L.1    Whitehead, J.K.2    Li, S.3
  • 65
    • 84856076539 scopus 로고    scopus 로고
    • Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart
    • Mir SA, Chatterjee A, Mitra A, et al. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem. 2012;287:2666-2677.
    • (2012) J Biol Chem. , vol.287 , pp. 2666-2677
    • Mir, S.A.1    Chatterjee, A.2    Mitra, A.3
  • 66
    • 79960396933 scopus 로고    scopus 로고
    • Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study
    • Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174.
    • (2011) Circulation. , vol.124 , pp. 164-174
    • Guazzi, M.1    Vicenzi, M.2    Arena, R.3
  • 67
    • 79551580284 scopus 로고    scopus 로고
    • PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study
    • Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
    • (2011) Circ Heart Fail. , vol.4 , pp. 8-17
    • Guazzi, M.1    Vicenzi, M.2    Arena, R.3
  • 68
    • 84875531214 scopus 로고    scopus 로고
    • Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
    • Redfield MM, Chen HH, Borlaug BA, et al; For the RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277.
    • (2013) JAMA. , vol.309 , pp. 1268-1277
    • Redfield, M.M.1    Chen, H.H.2    Borlaug, B.A.3
  • 69
    • 4344632810 scopus 로고    scopus 로고
    • Advanced glycation end product cross-linking: Pathophysiologic role and therapeutic target in cardiovascular disease
    • Zieman S, Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail. 2004;10:144-149.
    • (2004) Congest Heart Fail. , vol.10 , pp. 144-149
    • Zieman, S.1    Kass, D.2
  • 70
    • 66949125305 scopus 로고    scopus 로고
    • Molecular determinants of heart failure with normal left ventricular ejection fraction
    • Borbély A, Papp Z, Edes I, et al. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep. 2009;61:139-145.
    • (2009) Pharmacol Rep. , vol.61 , pp. 139-145
    • Borbély, A.1    Papp, Z.2    Edes, I.3
  • 71
    • 84868609067 scopus 로고    scopus 로고
    • The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction
    • Willemsen S, Hartog JW, van Veldhuisen DJ, et al. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J. 2012;164:742-749.
    • (2012) Am Heart J. , vol.164 , pp. 742-749
    • Willemsen, S.1    Hartog, J.W.2    Van Veldhuisen, D.J.3
  • 72
    • 16244371321 scopus 로고    scopus 로고
    • The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure
    • Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191-195.
    • (2005) J Card Fail. , vol.11 , pp. 191-195
    • Little, W.C.1    Zile, M.R.2    Kitzman, D.W.3
  • 73
    • 84867745957 scopus 로고    scopus 로고
    • The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial
    • Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators.
    • Solomon SD, Zile M, Pieske B, et al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380: 1387-1395.
    • (2012) Lancet. , vol.380 , pp. 1387-1395
    • Solomon, S.D.1    Zile, M.2    Pieske, B.3
  • 74
    • 33845736864 scopus 로고    scopus 로고
    • BiDil (isosorbide dinitrate and hydralazine): A new fixed-dose combination of two older medications for the treatment of heart failure in black patients
    • Carmody MS, Anderson J.R. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients. Cardiol Rev. 2007;15:46-53.
    • (2007) Cardiol Rev. , vol.15 , pp. 46-53
    • Carmody, M.S.1    Anderson, J.R.2
  • 75
    • 70349263587 scopus 로고    scopus 로고
    • Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure
    • Wilson RM, De Silva DS, Sato K, et al. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension. 2009;54:583-590.
    • (2009) Hypertension. , vol.54 , pp. 583-590
    • Wilson, R.M.1    De Silva, D.S.2    Sato, K.3
  • 76
    • 84856140884 scopus 로고    scopus 로고
    • Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy
    • Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-451.
    • (2012) J Am Coll Cardiol. , vol.59 , pp. 442-451
    • Schwartzenberg, S.1    Redfield, M.M.2    From, A.M.3
  • 77
    • 84875173419 scopus 로고    scopus 로고
    • Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction i hypertensive patients
    • Wang YC, Yu CC, Chiu FC, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction I hypertensive patients. J Card Fail. 2013;19:163-168.
    • (2013) J Card Fail. , vol.19 , pp. 163-168
    • Wang, Y.C.1    Yu, C.C.2    Chiu, F.C.3
  • 78
    • 84874875448 scopus 로고    scopus 로고
    • Soluble ST2 protein in chronic heart failure is independent of traditional factors
    • Wojtczak-Soska K, Pietrucha T, Sakowicz A, et al. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch Med Sci. 2013;9:21-26.
    • (2013) Arch Med Sci. , vol.9 , pp. 21-26
    • Wojtczak-Soska, K.1    Pietrucha, T.2    Sakowicz, A.3
  • 79
    • 79953813107 scopus 로고    scopus 로고
    • Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
    • Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
    • (2011) Blood. , vol.117 , pp. 3720-3732
    • Dinarello, C.A.1
  • 81
    • 84873027749 scopus 로고    scopus 로고
    • Mineralocorticoid receptormediated vascular insulin resistance: An early contributor to diabetesrelated vascular disease
    • Bender SB, McGraw AP, Jaffe IZ, et al. Mineralocorticoid receptormediated vascular insulin resistance: an early contributor to diabetesrelated vascular disease? Diabetes. 2013;62:313-319.
    • (2013) Diabetes , vol.62 , pp. 313-319
    • Bender, S.B.1    McGraw, A.P.2    Jaffe, I.Z.3
  • 82
    • 84861983900 scopus 로고    scopus 로고
    • Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation
    • Da̧browski R, Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J. 2012;19:223-229.
    • (2012) Cardiol J. , vol.19 , pp. 223-229
    • Da̧browski, R.1    Szwed, H.2
  • 83
    • 84856442152 scopus 로고    scopus 로고
    • Role of ranolazine in angina, heart failure, arrhythmias, and diabetes
    • Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311-323.
    • (2012) Pharmacol Ther. , vol.133 , pp. 311-323
    • Sossalla, S.1    Maier, L.S.2
  • 84
    • 80054119745 scopus 로고    scopus 로고
    • Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice
    • Cheang WS, Wong WT, Tian XY, et al. Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice. Cardiovasc Res. 2011;92:267-275.
    • (2011) Cardiovasc Res. , vol.92 , pp. 267-275
    • Cheang, W.S.1    Wong, W.T.2    Tian, X.Y.3
  • 85
    • 84873059357 scopus 로고    scopus 로고
    • Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension
    • Johnson AW, Kinzenbaw DA, Modrick ML, et al. Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension. Hypertension. 2013;61:437-442.
    • (2013) Hypertension. , vol.61 , pp. 437-442
    • Johnson, A.W.1    Kinzenbaw, D.A.2    Modrick, M.L.3
  • 86
    • 0037432184 scopus 로고    scopus 로고
    • Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations
    • Kawaguchi M, Hay I, Fetics B, et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-720.
    • (2003) Circulation. , vol.107 , pp. 714-720
    • Kawaguchi, M.1    Hay, I.2    Fetics, B.3
  • 87
    • 84877265606 scopus 로고    scopus 로고
    • Predictors of new-onset heart failure: Differences in preserved versus reduced ejection fraction
    • Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6:279-286.
    • (2013) Circ Heart Fail. , vol.6 , pp. 279-286
    • Ho, J.E.1    Lyass, A.2    Lee, D.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.